001476244 000__ 06870cam\\2200613Mu\4500
001476244 001__ 1476244
001476244 003__ OCoLC
001476244 005__ 20231003174639.0
001476244 006__ m\\\\\o\\d\\\\\\\\
001476244 007__ cr\cn\nnnunnun
001476244 008__ 230826s2023\\\\sz\a\\\\o\\\\\000\0\eng\d
001476244 019__ $$a1395067650
001476244 020__ $$a9783031353956
001476244 020__ $$a3031353951
001476244 020__ $$z3031353943
001476244 020__ $$z9783031353949
001476244 0247_ $$a10.1007/978-3-031-35395-6$$2doi
001476244 035__ $$aSP(OCoLC)1395183435
001476244 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dYDX$$dEBLCP
001476244 049__ $$aISEA
001476244 050_4 $$aTP248.65.V32
001476244 08204 $$a615.3/72$$223/eng/20230831
001476244 24500 $$aNanovaccinology :$$bclinical application of nanostructured materials research to translational medicine /$$cKaushik Pal, editor.
001476244 260__ $$aCham :$$bSpringer,$$c2023.
001476244 300__ $$a1 online resource (ix, 365 pages) :$$billustrations (chiefly color).
001476244 500__ $$aDescription based upon print version of record.
001476244 5050_ $$aIntro -- Preface -- Contents -- Chapter 1: Diversities of Various Nanomaterials-Based Vaccines for Healthcare Applications -- 1.1 Introduction -- 1.2 Role of Nanoparticles as Adjuvants in Vaccines -- 1.2.1 Nanoparticles in Vaccine -- 1.2.1.1 Nanoparticles as Adjuvants in Vaccines -- 1.2.2 Role of Metallic Nanoparticle -- 1.2.3 Carbohydrates Containing Nanoparticles as Vaccines -- 1.2.4 Polymer-Based Nanoparticles -- 1.2.5 Nanomaterial Vaccines -- 1.2.5.1 Concept of Nanomaterial-Based Vaccines -- 1.2.5.2 Current Market Scenario of Nanomaterial-Based Vaccines -- 1.2.6 Inorganic Nanoparticles
001476244 5058_ $$a1.2.6.1 Liposomes -- 1.2.6.2 VLPs (Virus-Like Particles) -- 1.2.6.3 Dendrimers -- 1.3 Applications of Nanomaterials-Based Vaccines in Healthcare -- 1.4 Challenges in the Development of Nano-Based Vaccines -- 1.5 Future Perspectives -- 1.6 Conclusions -- References -- Chapter 2: Nanomedicine: Insight Analysis of Emerging Biomedical Research and Developments -- 2.1 Scope of Nanomedicine -- 2.1.1 Nanomedicine: R&D in Prophylaxis -- 2.1.2 Nanomedicine: R&D in Diagnostics -- 2.1.3 Nanomedicine in Therapeutics -- 2.1.3.1 Nanomedicine in Drug Delivery -- 2.1.3.1.1 Polymer-Based Nanoparticles
001476244 5058_ $$a2.1.3.1.2 Lipid-Based NPs -- 2.1.3.1.3 Nonpolymeric Nanoparticles -- 2.2 Nanoparticles in Cancer Diagnosis -- 2.2.1 Nanoparticles in Bioimaging/Biosensing -- 2.2.2 Nanoparticles in Drug Delivery -- 2.3 Challenges in Nanomedicine R & D -- 2.4 Future Perspectives -- References -- Chapter 3: Nanomedicine: Therapeutic Approach of Vaccinology to Fight Against SARS/COVID-19 -- 3.1 Detection of SARS/COVID-19 -- 3.2 Diagnosis of SARS-CoV-2 -- 3.2.1 Colorimetric -- 3.2.2 Biosensor -- 3.3 Types of Nanocarrier for Delivery of Drugs -- 3.3.1 Liposomes -- 3.3.2 Dendrimer -- 3.3.3 Polymer-Based Nanoparticles
001476244 5058_ $$a3.3.4 Coating with PEG -- 3.3.5 Nanosuspension -- 3.3.6 Nanoemulsions -- 3.4 Conclusion -- References -- Chapter 4: Drug Delivery and Therapeutics for the Treatment of Infectious Diseases -- 4.1 Introduction -- 4.2 Conventional Drug Delivery and Therapeutics for Infectious Diseases -- 4.3 Drug Delivery Systems (DDS) to Combat Infectious Diseases -- 4.3.1 Polymer-Based Nanoparticulate Drug Delivery System -- 4.3.1.1 Dendrimers -- 4.3.1.2 Polymeric Micelles -- 4.3.1.3 Niosomes -- 4.3.1.4 Nanocapsules -- 4.3.1.5 Nanosphere -- 4.3.2 Lipid-Based NPs (LBNP) -- 4.3.2.1 Liposomes
001476244 5058_ $$a4.3.2.2 Solid Lipid NPs (SLN) -- 4.3.2.3 Nanostructured Lipid Carriers (NLCs) -- 4.3.3 Metal-Based Nanoparticulate Drug Delivery System -- 4.3.3.1 Metal Colloids -- 4.3.3.2 Carbon Nanotubes -- 4.3.3.3 Fullerene -- 4.3.3.4 Gold Nanoshells -- 4.3.3.5 Silicone NPs -- 4.3.3.6 Quantum Dots -- 4.3.4 Biologicals -- 4.4 Biomimetic/Bioinspired Nano Therapies to Combat Infectious Diseases -- 4.4.1 Biomimetic NPs for Treatment -- 4.4.2 Biomimetic/Bioinspired NPs as Vaccines -- 4.5 Oral Nanobiotics: Delivery and Therapy for Infectious Diseases -- 4.5.1 Benefits of Nanoantibiotics
001476244 506__ $$aAccess limited to authorized users.
001476244 520__ $$aThis book provides an overview of the cumulative work on a driving force for innovation in medicine and modern healthcare, boosting advances in therapeutics, biosensors, vaccines, and clinical systems. The work presented shows how nanoparticles have been investigated as vaccine adjuvants because they possess chemical and structural properties that improve immunogenicity as well as the use of nanotechnology in the construction of immunization systems that has developed into the field of viral nanovaccinology. The volume highlights potential areas of research, innovation, and development of finished products for future commercialization and significant research exploration through nanoparticles that prove capable of surmounting most of the barriers like toxicity issues, clearance from biological system, DNA instability, and differences in expression systems. The contributing authors review the primary literature on principles, limitations, and recent breakthroughs in nanoparticle-based antigen delivery vehicles, their use in different diseases, the major bottlenecks, and related issues. Highlighting advances in nanoparticle engineering and the understanding of nanoparticle characteristics as well as critical legacy work dome in the field of nanobiotechnology, the book is ideal for a range of researchers and students in the pure and applied sciences devoted to nanomaterials, vaccinology, and translational medicine. Explains unique trends of novel nanoparticles design, processing, and characterization for emerging nanovaccinology; Presents improvements of biosensors to prevent the need for multiple administrations of the vaccines; Discusses highly efficient and nontoxic vaccines to prevent virus infections.
001476244 650_0 $$aVaccines$$xBiotechnology.
001476244 650_0 $$aImmunological adjuvants.
001476244 650_0 $$aNanomedicine.
001476244 650_0 $$aNanobiotechnology$$xTherapeutic use.
001476244 655_0 $$aElectronic books.
001476244 7001_ $$aPal, Kaushik.
001476244 77608 $$iPrint version:$$aPal, Kaushik$$tNanovaccinology$$dCham : Springer International Publishing AG,c2023$$z9783031353949
001476244 852__ $$bebk
001476244 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-35395-6$$zOnline Access$$91397441.1
001476244 909CO $$ooai:library.usi.edu:1476244$$pGLOBAL_SET
001476244 980__ $$aBIB
001476244 980__ $$aEBOOK
001476244 982__ $$aEbook
001476244 983__ $$aOnline
001476244 994__ $$a92$$bISE